The US tariffs, which are looming over Indian drugs, could have wide-ranging implications for the US healthcare delivery system. With the US receiving almost half its generic medicines from India, the tariffs might raise healthcare expenditure and worsen drug shortages. Indian generics saved America $219 billion in 2022 alone, rendering them vital for universal healthcare at an affordable price. Tariffs are likely to worsen demand-supply imbalances, experts argue, hurting the uninsured and poor the most. The tariffs may boomerang by reducing access to healthcare for millions of Americans.
Source: BBC, NDTV, Financial Express